(277a) U.S. Fda Perspective on the Regulations of Cyanoacrylate Polymer Tissue Adhesives in Clinical Applications
- Conference: AIChE Annual Meeting
- Year: 2005
- Proceeding: 2005 Annual Meeting
- Group: Biomedical Applications of Nanotechnology (Bionanotechnology)
- Time: Tuesday, November 1, 2005 - 3:15pm-3:45pm
A brief description of the uses and clinical applications of synthetic cyanoacrylate polymer adhesive/glues that have been cleared and/or approved as medical devices by FDA since the Medical Device Amendments of 1976 were enacted. This includes cyanoacrylate Class I devices (Exempt and not Exempt devices), Class II cyanoacrylate devices such as Dental Cements and Orthodontic Bracket Adhesives, and Class III (PMA) devices such as Dermabond?, Indermil? Tissue Adhesive, and Trufill® n-Butyl Cyanoacrylate Embolic Agent. By citing an example of recently FDA approved Class III (PMA) devices in the Cyanoacrylate technology, the author provides a brief discussion of the FDA approval process of medical devices. It includes the FDA issues regarding the published guidance document for "Cyanoacrylate Topical Tissue Adhesives" that will provide guidance to regulatory personnel and manufacturers in the preparation of IDE applications and in the development of valid scientific evidence to support PMA applications for cyanocrylate tissue adhesives intended for topical approximation of skin and others. Also, the author provides a short regulatory description of US FDA; under what laws its operates, how FDA evaluates new devices for marketing, and how the device regulatory system works, for example, Class I, Class II, and Class III cyanoacrylate medical devices.
This paper has an Extended Abstract file available; you must purchase the conference proceedings to access it.
Do you already own this?
Log In for instructions on accessing this content.
|AIChE Graduate Student Members||Free|
|AIChE Undergraduate Student Members||Free|